Screener / SEC EDGAR /CIK 0001111928 /10-K filed Feb 23, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Technology · Semiconductors

IPG Photonics Corp IPGP

Compare with peers Embed
Earnings releases

Latest results release: Nov 3, 2026

8-K item 2.02, exhibit 99

What IPGP's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 3, 2026 · EX-99.1

IPG PHOTONICS ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

Open on SEC

Double-Digit Revenue Growth Driven by Strategic Initiatives Across Industrial and Advanced Solutions

November 3, 2026 - IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the third quarter ended September 30, 2026.

*Adjusted gross margin, adjusted EBITDA and adjusted earnings per diluted share include non-GAAP adjustments. A reconciliation from GAAP to non-GAAP metrics is provided in this earnings release.

“We delivered our fourth consecutive quarter of double-digit year-over-year revenue growth, with revenue above the midpoint of our guidance,” said Dr. Mark Gitin, Chief Executive Officer of IPG Photonics. “Our performance reflects the strength of our technology, disciplined execution, and continued progress in expanding our presence in attractive, higher-growth markets. Strong demand for our differentiated welding and additive manufacturing solutions drove growth in Industrial Solutions while disciplined execution of our key strategic initiatives across defense and semiconductor markets led to strong growth in Advanced Solutions. Additionally, I anticipate that our acquisition of Lumibird Medical, which is expected to close in the fourth quarter, will further strengthen our reach, accelerate growth across medical markets, and increase revenue in Advanced Solutions.”

Third quarter revenue of $288 million increased 15% year over year, driven by 12% growth in Industrial Solutions and 33% growth in Advanced Solutions. Changes in foreign exchange rates increased revenue by approximately 1%. Industrial Solutions sales, accounting for 83% of total revenue, were driven by strong performance in welding and additive manufacturing applications. Advanced Solutions sales improved, driven by higher sales in semico nductor and defense applications. Emerging growth products accounted for 52% of total revenue, down from 58% in the prior quarter due to product mix. By region, sales increased 14% in Asia and 33% in North America and decreased 1% in Europe on a year-over-year basis.

GAAP gross margin of 40.7% and adjusted gross margin of 41.0% increased year over year, driven by lower product costs and $5.0 million in net tariff refunds recorded in the period, partially offset by lower fixed cost absorption. Net income was $20 million, or $0.47 per diluted share, and a djusted EBITDA was $52 million and adjusted earnings per diluted share (EPS) was $0.61 in the third quarter. During the third quarter, IPG generated $46 million in cash flow from operations and spent $17 million on capital expenditures.

“Our third quarter book-to-bill was approximately one as we continued to see improved industrial demand and executed on our strategic growth initiatives, driving adoption for our differentiated laser and photonics solutions that deliver measurable value to customers. As we move forward, we remain focused on driving profitable growth through innovation, technology differentiation, and operational excellence across our portfolio, ” concluded Dr. Gitin.

For the fourth quarter of 2026, IPG expects revenue of $265 million to $295 million, adjusted gross margin between 37.0% and 40.0% and adjusted operating expenses of $91 million to $94 million. IPG anticipates delivering adjusted earnings per diluted share in the range of $0.30 to $0.60 and adjusted EBITDA in the range of $33 million to $50 million. The guidance assumes no contribution from the acquisition of Lumibird Medical.

As discussed in more detail in the "Safe Harbor" passage of this news release, actual results may differ from this guidance due to various factors including, but not limited to, trade policy changes and trade restrictions, product demand, order cancellations and delays, competition, tariffs and retaliatory tariffs, currency fluctuations and general economic conditions. The current uncertainty related to the trade environment and tariff policies increases the risks to the outlook that we have provided. This guidance is based upon current market conditions and expectations and is subject to the risks outlined in the Company's reports filed with the SEC and assumes exchange rates relative to the U.S. dollar of euro 0.88, Japanese yen 157 and Chinese yuan 6.74, respectively.

Additional supplemental financial information is provided in the unaudited Financial Data Workbook and Third Quarter 2026 Earnings Call Presentation available on the investor relations section of the Company's website at investor.ipgphotonics.com .

The Company will hold a conference call today, November 3, 2026 at 10:00 am ET. To access the call, please dial 877-407-6184 in the US or 201-389-0877 internationally. A live webcast of the call will also be available and archived on the investor relations section of the Company's website at investor.ipgphotonics.com .

Innovation is at the heart of IPG Photonics. As a global leader in laser technology, we apply light to transform the world. From manufacturing to medical and beyond, our breakthrough laser solutions power our customers’ success and expand what's possible. Discover more at www.ipgphotonics.com. 2

Information and statements provided by IPG and its employees, including statements in this press release, that relate to future plans, events or performance are forward-looking statements. These statements involve risks and uncertainties. Any statements in this press release that are not statements of historical fact are forward-looking statements, including those statements related to strength of our technology, disciplined execution, and continued progress in expanding our presence in attractive, higher-growth markets, the expected timing of the closing of our acquisition of Lumibird Medical and the expectation that the acquisition will increase revenue in Advanced Solutions and strengthen our reach and accelerate growth across medical markets, strategic growth initiatives, driving adoption for our differentiated laser and photonics solutions that deliver measurable value to customers, driving profitable growth through innovation, technology differentiation, and operational excellence across our portfolio, revenue, adjusted gross margin and adjusted operating expenses outlook, adjusted earnings per diluted share and adjusted EBITDA guidance, including the expected impact of tariffs, and the impact of the U.S. dollar on our guidance for the fourth quarter of 2026. Factors that could cause actual results to differ materially include risks and uncertainties, including risks associated with the strength or weakness of business conditions in industries and geographic markets that IPG serves, particularly the effect of downturns in the markets IPG serves; uncertainties and adverse changes in the general economic conditions of markets; inability to manage risks associated with international customers and operations; changes in trade controls and tariff policies; IPG's ability to penetrate new applications for fiber lasers and increase market share; the rate of acceptance and penetration of IPG's products; foreign currency fluctuations; high levels of fixed costs from IPG's vertical integration; the appropriateness of IPG's manufacturing capacity for the level of demand; competitive factors, including declining average selling prices; the effect of acquisitions and investments; inventory write-downs; asset impairment charges; intellectual property infringement claims and litigation; interruption in supply of key components; manufacturing risks; government regulations and trade sanctions; and other risks identified in IPG's SEC filings. Readers are encouraged to refer to the risk factors described in IPG's Annual Report on Form 10-K (filed with the SEC for the fiscal year ended December 31, 2025), IPG's Quarterly Report on Form 10-Q (filed with the SEC for the quarter ended June 30, 2026), and other reports filed with the SEC, as applicable. Actual results, events and performance may differ materially. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date hereof. IPG undertakes no obligation to update the forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. 3

September 30, 2026 (In thousands, ASSETS except share December 31, Current assets: data) 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 710,688 $ 403,790 equivalents Short-term 215,304 435,538 investments Accounts 191,150 181,734 receivable, net Inventories 337,890 313,416 Prepaid income 33,145 43,196 taxes Prepaid expenses and other 54,460 45,766 current assets Total current 1,542,637 1,423,440 assets Long-term — 76,533 investments Deferred income 122,235 123,889 taxes, net Goodwill 70,281 71,735 Intangible 42,777 49,933 assets, net Property, plant and equipment, 648,326 637,516 net Other assets 45,787 41,234 Total assets $ 2,472,043 $ 2,424,280 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 48,782 $ 39,288 Accrued expenses and other 204,874 184,849 current liabilities Income taxes 3,858 9,900 payable Total current 257,514 234,037 liabilities Other long-term liabilities and 59,581 62,113 deferred income taxes Total 317,095 296,150 liabilities Commitments and contingencies Stockholders' equity: Common stock, $0.0001 par value, 175,000,000 shares authorized; 57,380,668 and 42,508,140 shares issued and outstanding, respectively, at 6 6 September 30, 2026; 56,964,939 and 42,127,067 shares issued and outstanding, respectively, at December 31, 2025. Treasury stock, at cost, 14,872,528 and 14,837,872 shares held at -1,558,277 -1,555,629 September 30, 2026 and December 31, 2025, respectively. Additional 1,097,673 1,077,172 paid-in capital Retained 2,672,063 2,644,964 earnings Accumulated other -56,517 -38,383 comprehensive loss Total stockholders' 2,154,948 2,128,130 equity Total liabilities and $ 2,472,043 $ 2,424,280 stockholders' equity

Nine Months Ended September 30, Cash flows from 2026 operating activities: (In thousands) 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 27,099 $ 17,826 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 47,377 46,799 amortization Impairment charges 17,805 — Provisions for inventory, warranty & 33,594 31,766 bad debt Other 25,081 21,119 Changes in assets and liabilities that provided (used) cash: Accounts receivable 1,535 18,787 and accounts payable Inventories -60,189 -52,005 Other -13,771 -37,757 Net cash provided by operating 78,531 46,535 activities Cash flows from investing activities: Purchases of and deposits on property, -54,437 -60,907 plant and equipment Proceeds from sales of property, plant 2,204 605 and equipment Purchases of -360,732 -866,402 investments Purchases of equity -8,000 — investment Proceeds from maturities of 663,124 633,731 investments Deposit received from buyer for assets 2,000 — held for sale Other 111 69 Net cash provided by (used in) investing 244,270 -292,904 activities Cash flows from financing activities: Payments for taxes related to net share settlement of equity awards less proceeds from issuance -11,053 -4,316 of common stock under employee stock option and purchase plans Purchase of treasury stock net of excise -2,648 -46,603 tax, at cost Net cash used in -13,701 -50,919 financing activities Effect of changes in exchange rates on cash, cash equivalents -1,727 23,274 and cash held for sale Net increase (decrease) in cash, cash 307,373 -274,014 equivalents and cash held for sale Cash and cash equivalents — 403,790 620,040 Beginning of period Cash, cash equivalents and cash held for $ 711,163 $ 346,026 sale — End of period Supplemental disclosures of cash flow information: Cash paid for interest $ 54 $ 136 Cash paid for income taxes, net of $ 9,273 $ 44,258 refunds

We refer to certain financial measures that are not recognized under United States generally accepted accounting principles (“GAAP”) and are provided as supplemental information to enhance understanding of the Company’s financial performance. Such non-GAAP financial measures should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measure presented by the Company. The following information provides the definition of adjusted gross profit, adjusted gross margin, adjusted operating expense and resultant adjusted operating income, EBITDA, adjusted EBITDA, adjusted net income, adjusted net earnings per share (EPS), and adjusted tax rate as presented, which are financial measures that are not calculated or presented in accordance with GAAP, and reconciliation to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided adjusted gross profit, adjusted gross margin, adjusted operating expense and resultant adjusted operating income, EBITDA, adjusted EBITDA, adjusted net income, adjusted EPS, and an adjusted tax rate as supplemental information and in addition to the financial measures presented by the Company that are calculated and presented in accordance with GAAP. We define adjusted gross profit as reported gross profit, adjusted for non- recurring, infrequent, or unusual charges, including acquisition and integration charges and amortization of acquisition-related intangibles. We define adjusted gross margin as adjusted gross profit divided by total revenue. We define adjusted operating expense and resultant adjusted operating income as reported operating expenses and resultant operating income, adjusted for non- recurring, infrequent, or unusual charges, including impairment charges, settlement and fees of litigation matters, restructuring charges, acquisition and integration charges, amortization of acquisition-related intangibles, foreign exchange gains/losses and gain/loss on disposal of assets/divestiture. We define EBITDA as net income plus interest expense (income), provision for income taxes, depreciation expense, and amortization expense. We define adjusted EBITDA as EBITDA adjusted for non-recurring, infrequent, or unusual charges, and other adjustments that the Company believes appropriate, including stock-based compensation, restructuring charges, impairment charges, settlement and fees of litigation matters, acquisition and integration charges, foreign exchange gains/losses and gain/loss on disposal of assets/divestiture.

We define adjusted net income as reported net income, adjusted for non- recurring, infrequent, or unusual charges, and other adjustments that the Company believes appropriate, including impairment charges, settlement and fees of litigation matters, restructuring charges, amortization of acquisition- related intangibles, acquisition and integration charges, foreign exchange gains/losses and gain/loss on disposal of assets/divestiture, certain discrete tax items and non-GAAP income tax reconciling adjustments. We define adjusted EPS as adjusted net income divided by the weighted-average diluted shares outstanding.

We define adjusted tax rate as the GAAP tax rate, adjusted for discrete tax items and the net impact of non-GAAP adjustments.

Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. Specifically, these non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts.

In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors. However, these non-GAAP financial measures have limitations as an analytical tool and are not intended to be an alternative to financial measures prepared in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies. Management may, however, utilize other measures to illustrate performance in the future. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of our non-GAAP financial measures to their most directly comparable GAAP measures has been provided below. These non-GAAP measures exclude (i) amortization of acquisition-related intangibles, (ii) restructuring charges, (iii) acquisition and integration costs, (iv) impairment charges, (v) foreign 7

exchange gains/losses, (vi) interest income, (vii) benefit (provision) from income taxes, (viii) depreciation, (ix) amortization, (x) stock-based compensation, (xi) gain/loss on disposal of assets/divestiture, (xii) settlement and fees of litigation matters, (xiii) certain discrete tax items, and (xiv) non-GAAP income tax reconciling adjustments.

We have not provided a quantitative reconciliation of forward-looking Non-GAAP adjusted earnings per diluted share and adjusted EBITDA to their most directly comparable GAAP financial measures because we are unable to estimate with reasonable certainty the ultimate timing or amount of certain significant items without unreasonable efforts. This is due to the inherent difficulty of forecasting the timing and/or amount of various items that would impact adjusted earnings per diluted share and adjusted EBITDA. This includes items that have not yet occurred, are out of the Company’s control, cannot be reasonably predicted and/or for which there would not be any meaningful adjustment or difference. For the same reasons, the Company is unable to address the probable significance of the unavailable information. Our non-GAAP tax provision for the fiscal third quarter of 2026 is 23%. The difference between our GAAP income tax provision and our non-GAAP income tax provision is presented as non-GAAP income tax reconciling adjustments. 8

Reconciliation of GAAP to Non-GAAP Net Income, and GAAP to Non-GAAP Net Income per Share, Diluted

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
          IPG PHOTONICS ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS          
                                                                                
 Double-Digit Revenue Growth Driven by Strategic Initiatives Across Industrial  
                             and Advanced Solutions                             
                                                                                
                      Focused on Driving Margin Expansion                       
                                                                                
  MARLBOROUGH, Mass. –                                                          
                                                                                
November 3, 2026 - IPG Photonics Corporation (NASDAQ: IPGP) today reported
financial results for the third quarter ended September 30, 2026.
                                                                                
  …                                                                             
  …                                                                             
  …                                                                             
  …        T…                                    N…                             
  …        M…                                    M…                             
  …        E…                                    E…                             
  …        S…                                    S…                             
  …    2…  3…       2…           C…           …  3…       …           …         
 ────────────────────────────────────────────────────────────────────────────── 
  …    $   2…       $   2…           …  %     $  8…       $  7…          14  %  
  …        4…  %        3…  %                    3…  %       3…  %              
  …                                                                             
  …    $   2…       $   7…              NM    $  1…       $  9…              …  
  …                                                                             
  …        7…  %        3…  %                    2…  %       1…  %              
  …                                                                             
  …    $   2…       $   7…           …  %     $  2…       $  1…          52  %  
  …                                                                             
  …                                                                             
  …    $   0…       $   0…           …  %     $  0…       $  0…          50  %  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        4…  %        3…  %                    3…  %       3…  %              
  …                                                                             
  …    $   5…       $   3…           …  %     $  1…       $  1…          34  %  
  …                                                                             
  …                                                                             
  …                                                                             
  …    $   0…       $   0…           …  %     $  1…       $  0…          55  %  
  …                                                                             
  …                                                                             
                                                                                
*Adjusted gross margin, adjusted EBITDA and adjusted earnings per diluted share
include non-GAAP adjustments. A reconciliation from GAAP to non-GAAP metrics is
provided in this earnings release.

NM - not meaningful .
                                                                                
   Management Comments                                                          
                                                                                
“We delivered our fourth consecutive quarter of double-digit year-over-year
revenue growth, with revenue above the midpoint of our guidance,” said Dr. Mark
Gitin, Chief Executive Officer of IPG Photonics. “Our performance reflects the
strength of our technology, disciplined execution, and continued progress in
expanding our presence in attractive, higher-growth markets. Strong demand for
our differentiated welding and additive manufacturing solutions drove growth in
Industrial Solutions while disciplined execution of our key strategic
initiatives across defense and semiconductor markets led to strong growth in
Advanced Solutions. Additionally, I anticipate that our acquisition of Lumibird
Medical, which is expected to close in the fourth quarter, will further
strengthen our reach, accelerate growth across medical markets, and increase
revenue in Advanced Solutions.”
                                                                                
   Financial Highlights                                                         
                                                                                
                                                                                
       T…                                    N…                                 
       M…                                    M…                                 
       E…                                    E…                                 
  …    S…                                    S…                                 
  …    3…                                    3…                                 
  …    2…            …           C…          2…           …           C…        
 ────────────────────────────────────────────────────────────────────────────── 
  …    $   2…        $  2…           …  %    $   …        $  6…           …  %  
  …                                                                             
  …            4…           …        …  %           1…           …        5  %  
  …                                                                             
  …    $   2…        $  2…           …  %    $   …        $  7…           …  %  
                                                                                
                                       1                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
Third quarter revenue of $288 million increased 15% year over year, driven by
12% growth in Industrial Solutions and 33% growth in Advanced Solutions. Changes
in foreign exchange rates increased revenue by approximately 1%. Industrial
Solutions sales, accounting for 83% of total revenue, were driven by strong
performance in welding and additive manufacturing applications. Advanced
Solutions sales improved, driven by higher sales in semico nductor and defense
applications. Emerging growth products accounted for 52% of total revenue, down
from 58% in the prior quarter due to product mix. By region, sales increased 14%
in Asia and 33% in North America and decreased 1% in Europe on a year-over-year
basis.

GAAP gross margin of 40.7% and adjusted gross margin of 41.0% increased year
over year, driven by lower product costs and $5.0 million in net tariff refunds
recorded in the period, partially offset by lower fixed cost absorption. Net
income was $20 million, or $0.47 per diluted share, and a djusted EBITDA was $52
million and adjusted earnings per diluted share (EPS) was $0.61 in the third
quarter. During the third quarter, IPG generated $46 million in cash flow from
operations and spent $17 million on capital expenditures.
                                                                                
   Business Outlook and Financial Guidance                                      
                                                                                
“Our third quarter book-to-bill was approximately one as we continued to see
improved industrial demand and executed on our strategic growth initiatives,
driving adoption for our differentiated laser and photonics solutions that
deliver measurable value to customers. As we move forward, we remain focused on
driving profitable growth through innovation, technology differentiation, and
operational excellence across our portfolio, ” concluded Dr. Gitin.

For the fourth quarter of 2026, IPG expects revenue of $265 million to $295
million, adjusted gross margin between 37.0% and 40.0% and adjusted operating
expenses of $91 million to $94 million. IPG anticipates delivering adjusted
earnings per diluted share in the range of $0.30 to $0.60 and adjusted EBITDA in
the range of $33 million to $50 million. The guidance assumes no contribution
from the acquisition of Lumibird Medical.

As discussed in more detail in the "Safe Harbor" passage of this news release,
actual results may differ from this guidance due to various factors including,
but not limited to, trade policy changes and trade restrictions, product demand,
order cancellations and delays, competition, tariffs and retaliatory tariffs,
currency fluctuations and general economic conditions. The current uncertainty
related to the trade environment and tariff policies increases the risks to the
outlook that we have provided. This guidance is based upon current market
conditions and expectations and is subject to the risks outlined in the
Company's reports filed with the SEC and assumes exchange rates relative to the
U.S. dollar of euro 0.88, Japanese yen 157 and Chinese yuan 6.74, respectively.
                                                                                
   Supplemental Financial Information                                           
                                                                                
Additional supplemental financial information is provided in the unaudited
Financial Data Workbook and Third Quarter 2026 Earnings Call Presentation
available on the investor relations section of the Company's website at
investor.ipgphotonics.com .
                                                                                
  Conference Call Reminder                                                      
                                                                                
The Company will hold a conference call today, November 3, 2026 at 10:00 am ET.
To access the call, please dial 877-407-6184 in the US or 201-389-0877
internationally. A live webcast of the call will also be available and archived
on the investor relations section of the Company's website at
investor.ipgphotonics.com .
                                                                                
  Contact                                                                       
                                                                                
Eugene Fedotoff

Senior Director, Investor Relations

IPG Photonics Corporation

508-597-4713

[email protected]
                                                                                
  About IPG Photonics Corporation                                               
                                                                                
Innovation is at the heart of IPG Photonics. As a global leader in laser
technology, we apply light to transform the world. From manufacturing to medical
and beyond, our breakthrough laser solutions power our customers’ success and
expand what's possible. Discover more at www.ipgphotonics.com.
                                       2                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
  Safe Harbor Statement                                                         
                                                                                
Information and statements provided by IPG and its employees, including
statements in this press release, that relate to future plans, events or
performance are forward-looking statements. These statements involve risks and
uncertainties. Any statements in this press release that are not statements of
historical fact are forward-looking statements, including those statements
related to strength of our technology, disciplined execution, and continued
progress in expanding our presence in attractive, higher-growth markets, the
expected timing of the closing of our acquisition of Lumibird Medical and the
expectation that the acquisition will increase revenue in Advanced Solutions and
strengthen our reach and accelerate growth across medical markets, strategic
growth initiatives, driving adoption for our differentiated laser and photonics
solutions that deliver measurable value to customers, driving profitable growth
through innovation, technology differentiation, and operational excellence
across our portfolio, revenue, adjusted gross margin and adjusted operating
expenses outlook, adjusted earnings per diluted share and adjusted EBITDA
guidance, including the expected impact of tariffs, and the impact of the U.S.
dollar on our guidance for the fourth quarter of 2026. Factors that could cause
actual results to differ materially include risks and uncertainties, including
risks associated with the strength or weakness of business conditions in
industries and geographic markets that IPG serves, particularly the effect of
downturns in the markets IPG serves; uncertainties and adverse changes in the
general economic conditions of markets; inability to manage risks associated
with international customers and operations; changes in trade controls and
tariff policies; IPG's ability to penetrate new applications for fiber lasers
and increase market share; the rate of acceptance and penetration of IPG's
products; foreign currency fluctuations; high levels of fixed costs from IPG's
vertical integration; the appropriateness of IPG's manufacturing capacity for
the level of demand; competitive factors, including declining average selling
prices; the effect of acquisitions and investments; inventory write-downs; asset
impairment charges; intellectual property infringement claims and litigation;
interruption in supply of key components; manufacturing risks; government
regulations and trade sanctions; and other risks identified in IPG's SEC
filings. Readers are encouraged to refer to the risk factors described in IPG's
Annual Report on Form 10-K (filed with the SEC for the fiscal year ended
December 31, 2025), IPG's Quarterly Report on Form 10-Q (filed with the SEC for
the quarter ended June 30, 2026), and other reports filed with the SEC, as
applicable. Actual results, events and performance may differ materially.
Readers are cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date hereof. IPG undertakes no obligation
to update the forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events,
except as required by law.
                                       3                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                           IPG PHOTONICS CORPORATION                            
                                                                                
                                                                                
                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS                 
                                                                                
                                  (UNAUDITED)                                   
                                                                                
           Three                                                                
           Months                                                               
           Ended                                                                
           Septem…                                                              
           30,                                                                  
           2026                                                                 
           (In                                 Nine                             
           thousa…                             Months                           
           except                              Ended                            
           per                                 Septe…                           
           share                               30,                              
           data)              2025             2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Net      $        287,5…    $     250,792    $       831,577    $     729,3…  
  sales                                                                         
  Cost                                                                          
  of                170,4…          151,787            502,500          446,9…  
  sales                                                                         
  Gross             117,0…           99,005            329,077          282,3…  
  prof…                                                                         
  Oper…                                                                         
  expe…                                                                         
  Sales                                                                         
  and               23,934           23,771             72,286          73,753  
  mark…                                                                         
  Rese…                                                                         
  and               31,335           30,358             95,648          88,631  
  deve…                                                                         
  Gene…                                                                         
  and               37,502           35,092            110,139          102,7…  
  admi…                                                                         
  Sett…                                                                         
  of                     —                —             13,334               —  
  liti…                                                                         
  matt…                                                                         
  Impa…                231                —             17,805               —  
  char…                                                                         
  Rest…                  —              425                  —             425  
  char…                                                                         
  Loss                                                                          
  on                 3,275            1,504              2,293           7,013  
  fore…                                                                         
  exch…                                                                         
  Total                                                                         
  oper…             96,277           91,150            311,505          272,6…  
  expe…                                                                         
  Oper…             20,777            7,855             17,572           9,786  
  inco…                                                                         
  Other                                                                         
  inco…                                                                         
  net:                                                                          
  Inte…                                                                         
  inco…              7,688            7,283             21,720          22,728  
  net                                                                           
  Other                                                                         
  (exp…                -50              516              2,683           2,026  
  inco…                                                                         
  net                                                                           
  Total                                                                         
  other              7,638            7,799             24,403          24,754  
  inco…                                                                         
  Inco…                                                                         
  befo…                                                                         
  prov…             28,415           15,654             41,975          34,540  
  for                                                                           
  inco…                                                                         
  taxes                                                                         
  Prov…                                                                         
  for                8,142            8,191             14,876          16,714  
  inco…                                                                         
  taxes                                                                         
  Net      $        20,273    $       7,463    $        27,099    $     17,826  
  inco…                                                                         
  Net                                                                           
  inco…                                                                         
  per                                                                           
  comm…                                                                         
  shar…                                                                         
  Basic    $          0.48    $        0.18    $          0.64    $       0.42  
  Dilu…    $          0.47    $        0.18    $          0.63    $       0.42  
  Weig…                                                                         
  aver…                                                                         
  comm…                                                                         
  shar…                                                                         
  outs…                                                                         
  Basic             42,531           42,199             42,416          42,427  
  Dilu…             42,840           42,556             42,904          42,659  
                                                                                
                                       4                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                           IPG PHOTONICS CORPORATION                            
                                                                                
                                                                                
                     CONDENSED CONSOLIDATED BALANCE SHEETS                      
                                                                                
                                  (UNAUDITED)                                   
                                                                                
                      September 30,                                             
                      2026                                                      
                      (In thousands,                                            
  ASSETS              except share                    December 31,              
  Current assets:     data)                           2025                      
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash       $                    710,688    $                403,790  
  equivalents                                                                   
  Short-term                               215,304                     435,538  
  investments                                                                   
  Accounts                                 191,150                     181,734  
  receivable, net                                                               
  Inventories                              337,890                     313,416  
  Prepaid income                            33,145                      43,196  
  taxes                                                                         
  Prepaid expenses                                                              
  and other                                 54,460                      45,766  
  current                                                                       
  assets                                                                        
  Total current                          1,542,637                   1,423,440  
  assets                                                                        
  Long-term                                      —                      76,533  
  investments                                                                   
  Deferred income                          122,235                     123,889  
  taxes, net                                                                    
  Goodwill                                  70,281                      71,735  
  Intangible                                42,777                      49,933  
  assets, net                                                                   
  Property, plant                                                               
  and equipment,                           648,326                     637,516  
  net                                                                           
  Other assets                              45,787                      41,234  
  Total assets        $                  2,472,043    $              2,424,280  
  LIABILITIES AND                                                               
  EQUITY                                                                        
  Current                                                                       
  liabilities:                                                                  
  Accounts payable    $                     48,782    $                 39,288  
  Accrued expenses                                                              
  and other                                204,874                     184,849  
  current                                                                       
  liabilities                                                                   
  Income taxes                               3,858                       9,900  
  payable                                                                       
  Total current                            257,514                     234,037  
  liabilities                                                                   
  Other long-term                                                               
  liabilities and                           59,581                      62,113  
  deferred                                                                      
  income taxes                                                                  
  Total                                    317,095                     296,150  
  liabilities                                                                   
  Commitments and                                                               
  contingencies                                                                 
  Stockholders'                                                                 
  equity:                                                                       
  Common stock,                                                                 
  $0.0001 par                                                                   
  value,                                                                        
  175,000,000                                                                   
  shares                                                                        
  authorized;                                                                   
  57,380,668 and                                                                
  42,508,140                                                                    
  shares issued                                                                 
  and outstanding,                                                              
  respectively, at                               6                           6  
  September 30,                                                                 
  2026; 56,964,939                                                              
  and                                                                           
  42,127,067                                                                    
  shares issued                                                                 
  and                                                                           
  outstanding,                                                                  
  respectively, at                                                              
  December                                                                      
  31, 2025.                                                                     
  Treasury stock,                                                               
  at cost,                                                                      
  14,872,528 and                                                                
  14,837,872                                                                    
  shares held at                        -1,558,277                  -1,555,629  
  September 30,                                                                 
  2026 and                                                                      
  December 31,                                                                  
  2025,                                                                         
  respectively.                                                                 
  Additional                             1,097,673                   1,077,172  
  paid-in capital                                                               
  Retained                               2,672,063                   2,644,964  
  earnings                                                                      
  Accumulated                                                                   
  other                                    -56,517                     -38,383  
  comprehensive                                                                 
  loss                                                                          
  Total                                                                         
  stockholders'                          2,154,948                   2,128,130  
  equity                                                                        
  Total                                                                         
  liabilities and     $                  2,472,043    $              2,424,280  
  stockholders'                                                                 
  equity                                                                        
                                                                                
                                       5                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                           IPG PHOTONICS CORPORATION                            
                                                                                
                                                                                
                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS                 
                                                                                
                                  (UNAUDITED)                                   
                                                                                
                            Nine Months Ended                                   
                            September 30,                                       
  Cash flows from           2026                                                
  operating activities:     (In thousands)                      2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net income                $                         27,099    $       17,826  
  Adjustments to                                                                
  reconcile net income                                                          
  to                                                                            
  net cash provided by                                                          
  operating                                                                     
  activities:                                                                   
  Depreciation and                                    47,377            46,799  
  amortization                                                                  
  Impairment charges                                  17,805                 —  
  Provisions for                                                                
  inventory, warranty &                               33,594            31,766  
  bad                                                                           
  debt                                                                          
  Other                                               25,081            21,119  
  Changes in assets and                                                         
  liabilities that                                                              
  provided (used) cash:                                                         
  Accounts receivable                                  1,535            18,787  
  and accounts payable                                                          
  Inventories                                        -60,189           -52,005  
  Other                                              -13,771           -37,757  
  Net cash provided by                                                          
  operating                                           78,531            46,535  
  activities                                                                    
  Cash flows from                                                               
  investing activities:                                                         
  Purchases of and                                                              
  deposits on property,                              -54,437           -60,907  
  plant and equipment                                                           
  Proceeds from sales of                                                        
  property, plant                                      2,204               605  
  and equipment                                                                 
  Purchases of                                      -360,732          -866,402  
  investments                                                                   
  Purchases of equity                                 -8,000                 —  
  investment                                                                    
  Proceeds from                                                                 
  maturities of                                      663,124           633,731  
  investments                                                                   
  Deposit received from                                                         
  buyer for assets                                     2,000                 —  
  held for sale                                                                 
  Other                                                  111                69  
  Net cash provided by                                                          
  (used in) investing                                244,270          -292,904  
  activities                                                                    
  Cash flows from                                                               
  financing activities:                                                         
  Payments for taxes                                                            
  related to net share                                                          
  settlement of equity                                                          
  awards less                                                                   
  proceeds from issuance                             -11,053            -4,316  
  of common stock                                                               
  under employee stock                                                          
  option and purchase                                                           
  plans                                                                         
  Purchase of treasury                                                          
  stock net of excise                                 -2,648           -46,603  
  tax, at cost                                                                  
  Net cash used in                                   -13,701           -50,919  
  financing activities                                                          
  Effect of changes in                                                          
  exchange rates on                                                             
  cash, cash equivalents                              -1,727            23,274  
  and cash held for                                                             
  sale                                                                          
  Net increase                                                                  
  (decrease) in cash,                                                           
  cash                                               307,373          -274,014  
  equivalents and cash                                                          
  held for sale                                                                 
  Cash and cash                                                                 
  equivalents —                                      403,790           620,040  
  Beginning of                                                                  
  period                                                                        
  Cash, cash equivalents                                                        
  and cash held for         $                        711,163    $      346,026  
  sale — End of period                                                          
  Supplemental                                                                  
  disclosures of cash                                                           
  flow                                                                          
  information:                                                                  
  Cash paid for interest    $                             54    $          136  
  Cash paid for income                                                          
  taxes, net of             $                          9,273    $       44,258  
  refunds                                                                       
                                                                                
                                       6                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                           IPG PHOTONICS CORPORATION                            
                                                                                
        SUPPLEMENTAL SCHEDULE OF NON-GAAP FINANCIAL MEASURES (UNAUDITED)        
                                                                                
  Use of Non-GAAP Adjusted Financial Information                                
                                                                                
We refer to certain financial measures that are not recognized under United
States generally accepted accounting principles (“GAAP”) and are provided as
supplemental information to enhance understanding of the Company’s financial
performance. Such non-GAAP financial measures should not be considered superior
to, as a substitute for or alternative to, and should be considered in
conjunction with, the GAAP financial measure presented by the Company. The
following information provides the definition of adjusted gross profit, adjusted
gross margin, adjusted operating expense and resultant adjusted operating
income, EBITDA, adjusted EBITDA, adjusted net income, adjusted net earnings per
share (EPS), and adjusted tax rate as presented, which are financial measures
that are not calculated or presented in accordance with GAAP, and reconciliation
to the most directly comparable financial measures calculated and presented in
accordance with GAAP. The Company has provided adjusted gross profit, adjusted
gross margin, adjusted operating expense and resultant adjusted operating
income, EBITDA, adjusted EBITDA, adjusted net income, adjusted EPS, and an
adjusted tax rate as supplemental information and in addition to the financial
measures presented by the Company that are calculated and presented in
accordance with GAAP.
We define adjusted gross profit as reported gross profit, adjusted for non-
recurring, infrequent, or unusual charges, including acquisition and integration
charges and amortization of acquisition-related intangibles.
We define adjusted gross margin as adjusted gross profit divided by total
revenue.
We define adjusted operating expense and resultant adjusted operating income as
reported operating expenses and resultant operating income, adjusted for non-
recurring, infrequent, or unusual charges, including impairment charges,
settlement and fees of litigation matters, restructuring charges, acquisition
and integration charges, amortization of acquisition-related intangibles,
foreign exchange gains/losses and gain/loss on disposal of assets/divestiture.
We define EBITDA as net income plus interest expense (income), provision for
income taxes, depreciation expense, and amortization expense.
We define adjusted EBITDA as EBITDA adjusted for non-recurring, infrequent, or
unusual charges, and other adjustments that the Company believes appropriate,
including stock-based compensation, restructuring charges, impairment charges,
settlement and fees of litigation matters, acquisition and integration charges,
foreign exchange gains/losses and gain/loss on disposal of assets/divestiture.

We define adjusted net income as reported net income, adjusted for non-
recurring, infrequent, or unusual charges, and other adjustments that the
Company believes appropriate, including impairment charges, settlement and fees
of litigation matters, restructuring charges, amortization of acquisition-
related intangibles, acquisition and integration charges, foreign exchange
gains/losses and gain/loss on disposal of assets/divestiture, certain discrete
tax items and non-GAAP income tax reconciling adjustments.
We define adjusted EPS as adjusted net income divided by the weighted-average
diluted shares outstanding.

We define adjusted tax rate as the GAAP tax rate, adjusted for discrete tax
items and the net impact of non-GAAP adjustments.

Management believes that these non-GAAP financial measures provide additional
means of evaluating period-over-period operating performance. Specifically,
these non-GAAP financial measures provide management with additional means to
understand and evaluate the operating results and trends in our ongoing business
by eliminating certain non-cash expenses and other items that management
believes might otherwise make comparisons of our ongoing business with prior
periods more difficult, obscure trends in ongoing operations, or reduce
management’s ability to make useful forecasts.

In addition, management understands that some investors and financial analysts
find this information helpful in analyzing our financial and operational
performance and comparing this performance to our peers and competitors.
However, these non-GAAP financial measures have limitations as an analytical
tool and are not intended to be an alternative to financial measures prepared in
accordance with GAAP. In addition, it should be noted that these non-GAAP
financial measures may be different from non-GAAP measures used by other
companies. Management may, however, utilize other measures to illustrate
performance in the future. Investors are encouraged to review the reconciliation
of these non-GAAP measures to their most directly comparable GAAP financial
measures. A reconciliation of our non-GAAP financial measures to their most
directly comparable GAAP measures has been provided below. These non-GAAP
measures exclude (i) amortization of acquisition-related intangibles, (ii)
restructuring charges, (iii) acquisition and integration costs, (iv) impairment
charges, (v) foreign
                                       7                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
exchange gains/losses, (vi) interest income, (vii) benefit (provision) from
income taxes, (viii) depreciation, (ix) amortization, (x) stock-based
compensation, (xi) gain/loss on disposal of assets/divestiture, (xii) settlement
and fees of litigation matters, (xiii) certain discrete tax items, and (xiv)
non-GAAP income tax reconciling adjustments.

We have not provided a quantitative reconciliation of forward-looking Non-GAAP
adjusted earnings per diluted share and adjusted EBITDA to their most directly
comparable GAAP financial measures because we are unable to estimate with
reasonable certainty the ultimate timing or amount of certain significant items
without unreasonable efforts. This is due to the inherent difficulty of
forecasting the timing and/or amount of various items that would impact adjusted
earnings per diluted share and adjusted EBITDA. This includes items that have
not yet occurred, are out of the Company’s control, cannot be reasonably
predicted and/or for which there would not be any meaningful adjustment or
difference. For the same reasons, the Company is unable to address the probable
significance of the unavailable information.
Our non-GAAP tax provision for the fiscal third quarter of 2026 is 23%. The
difference between our GAAP income tax provision and our non-GAAP income tax
provision is presented as non-GAAP income tax reconciling adjustments.
                                       8                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                           IPG PHOTONICS CORPORATION                            
                                                                                
             SUPPLEMENTAL SCHEDULE OF NON-GAAP MEASURES (UNAUDITED)             
Reconciliation of Gross Profit to Adjusted Gross Profit, Adjusted Gross Margin
                                                                                
          Three                                                                 
          Mont…                                                                 
          Ended                                                                 
          Sept…                                                                 
          30,                                 Nine                              
          2026                                Mont…                             
          (in                                 Ended                             
          thou…                               Sept…                             
          exce…                               30,                               
          perc…             2025              2026               2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Gro…    $        117,…    $       99,005    $        329,0…    $       282,…  
  pro…                                                                          
  Gro…             40.7%             39.5%              39.6%            38.7%  
  mar…                                                                          
  Amo…                                                                          
  of                 720               851              2,360            2,928  
  acq…                                                                          
  int…                                                                          
  Acq…                                                                          
  and                  —                 —                  —              482  
  int…                                                                          
  cha…                                                                          
  Adj…                                                                          
  gro…    $        117,…    $       99,856    $        331,4…    $       285,…  
  pro…                                                                          
  Adj…                                                                          
  gro…             41.0%             39.8%              39.9%            39.2%  
  mar…                                                                          
                                                                                
Reconciliation of Operating Expenses to Adjusted Operating Expenses
                                                                                
        Thr…                                                                    
        Mon…                                                                    
        End…                                 Nine                               
        Sep…                                 Mon…                               
        30,                                  End…                               
        2026                                 Sep…                               
        (in                                  30,                                
        tho…               20…               2026               20…             
 ────────────────────────────────────────────────────────────────────────────── 
  O…    $          96,…    $          91…    $          311…    $          27…  
  e…                                                                            
  L…                                                                            
  A…                                                                            
  of               1,2…               1,…               3,7…               4,…  
  a…                                                                            
  i…                                                                            
  A…                                                                            
  a…                151               246                987               1,…  
  i…                                                                            
  c…                                                                            
  I…                231                 —               17,…                 —  
  c…                                                                            
  R…                149               425                500               425  
  c…                                                                            
  S…                                                                            
  a…                                                                            
  f…                  —                 —               14,…                 —  
  of                                                                            
  l…                                                                            
  m…                                                                            
  L…                                                                            
  on               3,2…               1,…               2,2…               7,…  
  f…                                                                            
  e…                                                                            
  A…                                                                            
  o…    $     91…          $    87,…         $     27…          $    258…       
  e…                                                                            
                                                                                
Reconciliation of Operating Income to Adjusted Operating Income
                                                                                
        Thr…                                                                    
        Mon…                                                                    
        End…                                 Nine                               
        Sep…                                 Mon…                               
        30,                                  End…                               
        2026                                 Sep…                               
        (in                                  30,                                
        tho…               20…               2026               20…             
 ────────────────────────────────────────────────────────────────────────────── 
  O…    $          20,…    $          7,…    $          17,…    $          9,…  
  i…                                                                            
  A…                                                                            
  of               1,9…               2,…               6,0…               7,…  
  a…                                                                            
  i…                                                                            
  A…                                                                            
  a…                151               246                987               2,…  
  i…                                                                            
  c…                                                                            
  I…                231                 —               17,…                 —  
  c…                                                                            
  R…                149               425                500               425  
  c…                                                                            
  S…                                                                            
  a…                                                                            
  f…                  —                 —               14,…                 —  
  of                                                                            
  l…                                                                            
  m…                                                                            
  L…                                                                            
  on               3,2…               1,…               2,2…               7,…  
  f…                                                                            
  e…                                                                            
  A…                                                                            
  o…    $     26…          $    12,…         $     59…          $    27,…       
  i…                                                                            
                                                                                
                                       9                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
  Reconciliation of Net income to Adjusted EBITDA                               
                                                                                
                                                                                
          Three                                                                 
          Mont…                                                                 
          Ended                               Nine                              
          Sept…                               Mont…                             
          30,                                 Ended                             
          2026                                Sept…                             
          (in                                 30,                               
          thou…             2025              2026               2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net     $        20,2…    $        7,463    $        27,099    $       17,8…  
  inc…                                                                          
  Int…                                                                          
  inc…             -7,6…            -7,283             -21,7…            -22,…  
  net                                                                           
  Pro…                                                                          
  for              8,142             8,191             14,876            16,7…  
  inc…                                                                          
  tax…                                                                          
  Dep…             12,9…            12,392             38,447            36,1…  
  Amo…             2,976             3,240              8,930            10,6…  
  EBI…    $        36,6…    $       24,003    $        67,632    $       58,6…  
  Imp…               231                 —             17,805                —  
  cha…                                                                          
  Sto…                                                                          
  bas…             11,0…            10,780             31,597            32,8…  
  com…                                                                          
  Res…               149               425                500              425  
  cha…                                                                          
  Acq…                                                                          
  and                151               246                987            2,305  
  int…                                                                          
  cha…                                                                          
  Set…                                                                          
  and                                                                           
  fees                 —                 —             14,435                —  
  of                                                                            
  lit…                                                                          
  mat…                                                                          
  Loss                                                                          
  on               3,275             1,504              2,293            7,013  
  for…                                                                          
  exc…                                                                          
  Adj…    $        51,5…    $       36,958    $        135,2…    $       101,…  
  EBI…                                                                          
                                                                                
Reconciliation of GAAP to Non-GAAP Net Income, and GAAP to Non-GAAP Net Income
per Share, Diluted
                                                                                
            Three                                                               
            Months                                                              
            Ended                                                               
            Septem…                                                             
            30,                                                                 
            2026                                                                
            (in                                Nine                             
            thousa…                            Months                           
            except                             Ended                            
            per                                Septem…                          
            share                              30,                              
            data)              2025            2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Net       $        20,273    $      7,463    $        27,099    $     17,826  
  income                                                                        
  Impai…                231               —             17,805               —  
  charg…                                                                        
  Amort…                                                                        
  of                  1,951           2,402              6,061           7,498  
  acqui…                                                                        
  intan…                                                                        
  Restr…                149             425                500             425  
  charg…                                                                        
  Acqui…                                                                        
  and                   151             246                987           2,305  
  integ…                                                                        
  charg…                                                                        
  Settl…                                                                        
  and                                                                           
  fees                    —               —             14,435               —  
  of                                                                            
  litig…                                                                        
  matte…                                                                        
  Loss                                                                          
  on                  3,275           1,504              2,293           7,013  
  forei…                                                                        
  excha…                                                                        
  Certa…                                                                        
  discr…                949           3,414                 84           8,303  
  tax                                                                           
  items                                                                         
  Tax                                                                           
  impact                                                                        
  of                   -711            -613             -5,337          -2,471  
  non-G…                                                                        
  adjus…                                                                        
  Adjus…                                                                        
  net       $        26,268    $     14,841    $        63,927    $     40,899  
  income                                                                        
  Adjus…                                                                        
  net                                                                           
  earni…    $          0.61    $       0.35    $          1.49    $       0.96  
  per                                                                           
  dilut…                                                                        
  share                                                                         
  Weigh…                                                                        
  avera…                                                                        
  dilut…             42,840          42,556             42,904          42,659  
  shares                                                                        
  outst…                                                                        
                                                                                
Reconciliation of GAAP to Non-GAAP Effective Tax Rate
                                                                                
              Three                               Nine                          
             Months                             Months                          
              Ended                              Ended                          
            Septem…                           Septemb…                          
                30,                                30,                          
               2026           2025                2026            2025          
  Tax                29  %           52  %               35  %           48  %  
  rate                                                                          
  Discr…                                                                        
  tax                -3  %          -22  %                —  %          -24  %  
  items                                                                         
  Net                                                                           
  impact                                                                        
  of                 -3  %           -3  %              -11  %           -3  %  
  non-G…                                                                        
  adjus…                                                                        
  Adjus…                                                                        
  tax                23  %           27  %               24  %           21  %  
  rate                                                                          
                                                                                
                                       10                                       

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IPGP/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.